Pharmacoeconomic considerations in the management of hypertension

Drugs

Volumn 59, Issue SUPPL. 2, 2000, Pages 13-20

  Pardell, Helios ^a,b,c   Tresserras, Ricard ^b   Armario, Pedro ^a   Hernández Del Rey, Raquel ^a  

^a U Hypertension and Cardiovasc Risk   (Spain)

^b GENERALITAT DE CATALUNYA   (Spain)

^c Red Cross Centre   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIURETIC AGENT; SIMVASTATIN;

CARDIOVASCULAR RISK; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG CHOICE; DRUG COST; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFE EXPECTANCY; LIFESTYLE; LONG TERM CARE; MORBIDITY; MORTALITY; PREVALENCE; REVIEW;

EID: 0033966109     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200059002-00002     Document Type: Review

References (62)

1. Murray CJL, López AD, editors. The global burden of disease. Cambridge, MA: Harvard University Press, 1996
2. Gross CP, Anderson GF, Powe NR. The relation between funding by the National Institutes of Health and the burden of disease. N Engl J Med 1999; 340: 1881-7
3. O'Brien E, Staessen JA. What is 'hypertension'? Lancet 1999; 353: 1541-3
4. Hypertension Control. Report of a WHO Expert Committee. WHO Technical Report Series 862. Geneva: World Health Organization, 1996
5. Pardell H, Armario P, Hernández R, et al. Hypertension. Epidemiology and cost of illness. Dis Manage Health Outcomes 1997; 1: 135-40
6. World Health Organization, International Society of Hypertension. 1999 WHO-ISH guidelines for the management of hypertension. J Hypertens 1999; 17: 151-83
7. Kannel WB. Blood pressure as a cardiovascular risk factor. Prevention and treatment. JAMA 1996; 275: 1571-6
8. Merrill RM, Kessler LG, Udler JM, et al. Comparison of risk estimates for selected diseases and causes of death. Prev Med 1999; 28: 179-93
9. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and disatolic, and cardiovascular risks: US population data. Arch Intern Med 1993; 153: 598-615
10. Thom T. The economic costs of cardiovascular diseases in the United States, 1990. Bethesda, MD: National Heart, Lung and Blood Institute, 1993
11. Dustan HP, Roccella EJ, Garrison HH. Controlling hypertension. A research success story. Arch Intern Med 1996; 156: 1926-35
12. Schauffer H, D'Agostino R, Kannel WB. Risk for cardiovascular disease in the elderly and associated Medicare costs: The Framingham Study. Am J Prev Med 1993; 9: 146-54
13. Badia X, Rovira J, Tresserras R, et al. The cost of arterial hypertension in Spain. Med Clin (Barc) 1992; 99: 769-73
14. Pardell H, editor. Pharmacoeconomics of arterial hypertension. Madrid: Spanish Society of Hypertension/Spanish League against Arterial Hypertension, 1996
15. Johannesson M, Jönsson B. Cost-effectiveness analysis of hypertension treatment. A review of methodological issues. Health Policy 1991; 19: 55-78
16. Moser M. The cost of treating hypertension. Can we keep it under control without compromising the level of care? Am J Hypertens 1998; 11: 120S-7
17. Johannesson M, Borgquist L, Jönsson B. The costs of treating hypertension in Sweden: an empirical investigation in primary health care. Scand J Prim Health Care 1991; 9 (3): 155-60
18. Kawachi I, Malcolm LA. Treating mild to moderate hypertension. Cost-effectiveness and policy implications. J Cardiovasc Pharmacol 1990; 16 Suppl. 7: S126-8
19. Stason WB, Weinstein MC. Allocation of resources to manage hypertension. N Engl J Med 1977; 296: 732-9
20. Johannesson M. The cost-effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 1995; 7: 242-50
21. Mosterd A, D'Agostino RB, Silbershatz H, et al. Trends in the prevalence of hypertension, antihypertensive therapy, and left ventricular hypertrophy from 1950 to 1989. N Engl J Med 1999; 340: 1221-7
22. National Health Survey, 1995. Madrid: Ministry of Health and Consumer Affairs, 1996
23. Christiansen T, Pedersen KM, Harvald B, et al. A health economic investigation of the effect of treatment for hypertension. Odense: Odense University Research Report 6, 1987
24. Ménard J, Cornu PH, Day M. Cost of hypertension treatment and the price of health. J Hum Hypertens 1992; 6: 447-58
25. Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J Hypertens 1996; 14 Suppl. 2: S47-54
26. Prieto M, de Abajo FJ, Montero D, et al. Antihypertensive drugs use in Spain, 1985-1995. Med Clin (Barc) 1998; 110: 247-53
27. O'Brien B. Patterns of European diagnosis and prescribing. London: Office of Health Economics, 1984
28. OECD Health Data. Paris: Organization for Economic Cooperation and Development, 1997
29. The National High Blood Pressure Education program. Bethesda, MD: National Institutes of Health, 1988
30. Pardell H, Bohigas L. Economic perspective of the health problem of hypertension. In: Consulta SA, editor. International Society of Hypertension. 1988 Hypertension Yearbook. Barcelona: 1989 [Spanish edition]: 1-13
31. Koopmanschap MA, Rutten FFH. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996; 10: 460-6
32. Russell LB. Cost-effectiveness of antihypertensive treatment. General considerations. Hypertension 1989; 13 (5 Suppl.): I141-4
33. MacMahon SW, Cutler JA, Furberg CD, et al. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986; 29 Suppl. 1: S99-118
34. Collins R, Peto R, MacMahon SW, et al. Blood pressure, stroke and coronary heart disease. Pt 2. Effects of short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827-38
35. Mancia G, Cattaneo BM, Omboni S, et al. Clinical benefits of a consistent reduction in blood pressure. J Hypertens 1998; 16 Suppl. 6: S35-9
36. Sytkowski PA, D'Agostino RB, Belanger AJ, et al. Secular trends in long-term sustained hypertension, long-term treatment, and cardiovascular mortality. The Framingham Heart Study 1950 to 1990. Circulation 1996; 93: 697-703
37. MacMahon S, Cutler JA, Stamler J. Antihypertensive drug treatment. Potential, expected, and observed effects on stroke and on coronary heart disease. Hypertension 1989; 13 (5 Suppl.): I45-50
38. Tsevat J, Weinstein MC, Williams LW, et al. Expected gains in life expectancy from various coronary heart disease risk factor modifications. Circulation 1991; 83: 1194-201
39. Haapanen-Niemi N, Vuori I, Pasanen M. Public health burden of coronary heart disease risk factors among middle-aged and elderly men. Prev Med 1999; 28: 343-8
40. Zanchetti A, Mancia G. Editors' corner: strategies for antihypertensive treatment decisions: how to assess benefits? J Hypertens 1997; 15: 215-6
41. Madhavan S, Alderman MH. The potential effect of blood pressure reduction on cardiovascular disease. A cautionary note. Arch Intern Med 1981; 141: 1583-6
42. Ménard J, Chatellier G. Mild hypertension: the mysterious viability of a faulty concept. J Hypertens 1995; 13: 1071-7
43. Simpson FO. Guidelines for antihypertensive therapy: problems with a strategy based on absolute cardiovascular risk. J Hypertens 1996; 14: 683-9
44. MacMahon S. Guidelines for antihypertensive therapy. J Hypertens 1996; 14: 691-3
45. Zanchetti A, Mancia G. Editors' corner: benefits and cost-effectiveness of antihypertensive therapy. The actuarial versus the intervention trial approach. J Hypertens 1996; 14: 809-11
46. Robson J. Information needed to decide about cardiovascular treatment in primary care. BMJ 1997; 314: 277-80
47. Grover SA, Paquet S, Levinton C, et al. Estimating the benefits of modifying risk factors of cardiovascular disease. A comparison of primary prevention vs secondary prevention. Arch Intern Med 1998; 158: 655-62
48. Alderman MH. Blood pressure management: individualized treatment based on absolute risk and the potential for benefit. Ann Intern Med 1993; 119: 329-35
49. Ambrosioni E, Costa FV. Cost-effectiveness calculations from trials. J Hypertens 1996; 14 Suppl. 2: S47-54
50. Zanchetti A. Cost-effectiveness of antihypertensive therapy: what message to patients and health services? J Hypertens 1998; 16 Suppl. 9: S21-3
51. Weinstein MC, Stason WB. Hypertension. A policy perspective. Cambridge, MA: Harvard University Press, 1976
52. Johannesson M, Jönsson B. A review of cost-effectiveness analyses of hypertension treatment. Pharmacoeconomics 1992; 1: 250-64
53. Johannesson M, Borgquist L, Jönsson B, et al. The costs of treating hypertension - an analysis of different cut-off points. Health Policy 1991; 18: 141-50
54. Maynard Ȧ. The economics of hypertension control: some basic issues. J Hum Hypertens 1992; 6: 417-20
55. Field K, Thorogood M, Silagy C, et al. Strategies for reducing coronary risk factors in primary care: which is most cost-effective? BMJ 1995; 310: 1109-12
56. UK Prospective Diabetes Study Group. Cost-effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ 1998; 317: 720-6
57. Stason WB. Cost and quality trade-offs in the treatment of hypertension. Hypertension 1989; 13 (5 Suppl.): I145-8
58. Hilleman DE, Mohiuddin SM, Lucas D, et al. Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. Clin Ther 1994; 16: 88-102
59. Stason WB. Opportunities for improving the cost-effectiveness of antihypertensive therapy. Am J Med 1986; 81 Suppl. 6C: S45-9
60. Kawachi I, Malcolm LA. The cost-effectiveness of treating mild-to-moderate hypertension: a reappraisal. J Hypertens 1991; 9: 199-208
61. Dickerson JEC, Hingorani A, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353: 2008-13
62. Ramsay LE, ul Haq I, Yeo WW, et al. Interpretation of prospective trials in hypertension: do treatment guidelines accurately reflect current evidence? J Hypertens Suppl. 1996; 14 (5): S187-94